Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria
暂无分享,去创建一个
Min Zhang | Qingju Liu | Xia Gao | Min Zhang | Yanhong Suo | Yan Wang | Xia Gao | Xin Gao | Qiu Bing | Y. Suo | Qiu Bing
[1] D. Rader,et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoproteins , 2018 .
[2] Chad A. Cowan,et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. , 2018, Atherosclerosis.
[3] A. Grover,et al. Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients , 2016, Indian heart journal.
[4] Rui Zhang,et al. Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice* , 2016, The Journal of Biological Chemistry.
[5] L. Donini,et al. Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism1[S] , 2016, Journal of Lipid Research.
[6] Jonathan C. Cohen,et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis , 2015, Proceedings of the National Academy of Sciences.
[7] I. Pastan,et al. Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis. , 2015, The American journal of pathology.
[8] Jonathan C. Cohen,et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys1[S] , 2015, Journal of Lipid Research.
[9] Michiyasu Takeyama,et al. Human apolipoprotein B transgenic SHR/NDmcr-cp rats show exacerbated kidney dysfunction , 2015, Experimental animals.
[10] L. Hao,et al. Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat / high-cholesterol diet and low-dose streptozotocin , 2015, BMC Nephrology.
[11] X. Zha,et al. A vital role for Angptl3 in the PAN-induced podocyte loss by affecting detachment and apoptosis in vitro , 2015, BMC Nephrology.
[12] Duan Ma,et al. A novel role of angiopoietin-like-3 associated with podocyte injury , 2015, Pediatric Research.
[13] Yuanxiu Huang,et al. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control , 2014, Population Health Metrics.
[14] Mahboob Rahman,et al. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[15] M. Tonelli,et al. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. , 2014, Kidney international.
[16] H. J. Kim,et al. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] X. Zha,et al. Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by altering nephrin expression in vitro. , 2010, Biochemical and biophysical research communications.
[18] R. Bohle,et al. Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice , 2010, BMC nephrology.
[19] Zhihe Liu,et al. Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell Death* , 2008, Journal of Biological Chemistry.
[20] Kenichi Yoshida,et al. ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase* , 2002, The Journal of Biological Chemistry.
[21] B. Kasiske,et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. , 1988, Kidney international.